Market news

LeMaitre Vascular (LMAT) is drawing fresh attention after its shares closed at US$80.58, with recent returns showing modest gains over the past month and a decline over the past 3 months. Viewed over a longer stretch, LeMaitre Vascular’s 1 year total shareholder return is down 7.29%, even as the 3 year total shareholder return of 54.81% and 5 year total shareholder return of 56.88% point to earlier strength that has cooled with the recent 90 day share price pullback of 14.21% from current...

LeMaitre Vascular has delivered a 56.9% share price gain over the past five years, yet its recent flat patch raises a simple question for you as an investor. Are the cash flows from this medical device business strong and reliable enough to support where the stock trades today? That 56.9% move over five years puts real weight on whether LeMaitre Vascular's cash generation can support the value the market now assigns to the business. The company focuses on vascular devices that can support...

Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]

BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences. Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026, in BostonDorian LeBlanc, CFO, will participate in a Fireside Chat at 8:45 AM ET Morgan Stanley 24th Annual Global Healthcare Conference Wednesday, September 16, 2026, in New York CityDorian LeBlanc, CFO, will participate in a Fireside Chat at 12:

Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season.

LeMaitre Vascular stock remains a Buy after a 31% pullback. Click to see LMAT's Q2 drivers, Artegraft growth, margin upside, and valuation reset.

LeMaitre’s second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and Asia. However, the quarter fell short of Wall Street’s revenue and profit expectations, which contributed to a negative market reaction. Management attributed the underperformance to a combination of adverse currency impacts, ongoing Middle East export delays, and supply constraints in cardiac allografts. CEO George LeMaitre highlighted that,

Detailed price information for Lemaitre Vascular (LMAT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Lemaitre Vascular (LMAT-Q) from The Globe and Mail including charting and trades.

LeMaitre Vascular (LMAT) has an average rating of overweight and mean price target of $116.25, accor

Detailed price information for Booking Holdings (BKNG-Q) from The Globe and Mail including charting and trades.

Detailed price information for Lemaitre Vascular (LMAT-Q) from The Globe and Mail including charting and trades.

Moby summary of LeMaitre Vascular, Inc.'s Q2 2026 earnings call

LeMaitre Vascular (LMAT) has an average rating of overweight and mean price target of $116.25, accor

LeMaitre Vascular Inc (LMAT) reports 10% organic sales growth and 23% EPS growth in Q2 2026, driven by Artegraft and margin expansion, despite FX headwinds and supply challenges.

LeMaitre (LMAT) delivered earnings and revenue surprises of -8.64% and -1.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q2 2026: Sales $70.4mm, +10% (+10% organic) vs. Q2 2025Gross margin 72.1% (+210 bps)Op. income $20.4mm (+26%) Op. margin 29%EPS $0.74 (+23%)Cash up $9.0mm sequentially to $376.2mm Artegraft sales increased 34% in the quarter. Grafts (+23%), carotid

LeMaitre Vascular (NASDAQ:LMAT) reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relati

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 million. Next quarter’s revenue guidance of $67.3 million underwhelmed, coming in 3% below analysts’ estimates. Its GAAP profit of $0.74 per share was 8.3% below analysts’ consensus estimates.

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here’s what you need to know.

Detailed price information for Lemaitre Vascular (LMAT-Q) from The Globe and Mail including charting and trades.

BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them t